The Effect of Intranasally Administered Nitroglycerin on Hemodynamic Response to Laryngoscopy and Intubation Among Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery

NCT06637956 | Completed

• 1 other identifier: PIC_Lahore
• Study Type: interventional
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

Numerous preventive medications have been used to lessen the cardiovascular response to laryngoscopy and intubation. Though some advantages have been noted, most of these treatments have not been found to be completely satisfying. However, nitroglycerin is the most widely utilized medicine due to its fast effect, short half-life, and absence of sedative qualities.

Conditions

Coronary Artery Bypass Grafting

Keywords

Intranasal; nitroglycerin; hemodynamic response; larayngoscopy; intubation; coronary artery bypass grafting

Outcome Measures

Primary Outcomes (4)

• Mean aterial pressure

  Mean arterial pressure was measured prior to and after intubation

  5 minutes post intubation

• Heart rate

  Heart rate was measure prior to and after intubation

  5 minutes post intubation

• Systolic blood pressure

  Systolic blood pressure was measure prior to and after itubation

  5 minutes post intubation

• Diastolic blood pressure

  Diastolic blood pressure was measure prior to and after intubation

  5 minutes post intubation

Study Arms (2)

NTG

EXPERIMENTAL

Received a mg nitroglycerin intranasally two minutes prior to laryngoscopy and intubation

Drug: Nitroglycerin (NTG)

Control

NO INTERVENTION

Control group did not receive nitroglycerine prior to laryngoscopy and intubation

Interventions

Nitroglycerin (NTG) DRUG

Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation

NTG

Eligibility Criteria

• Age: 35 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Both genders
• Patients undergoing coronary artery bypass grafting surgery.
• Patients aged 35-60 years.
• Ejection Fraction between 50-60%.
• American Society of Anesthesiologists Classification 3-4.

You may not qualify if:

• Known hypersensitivity to nitroglycerin.
• Anticipated difficult airway.
• Emergency surgery.

Sponsors & Collaborators

• Muhammad Aamir Latif: lead

Study Sites (1)

Department of Anesthesia, Rashid Latif Medical College

Lahore, Punjab Province, Pakistan

Location

MeSH Terms

Interventions

Nitroglycerin

Intervention Hierarchy (Ancestors)

Nitro Compounds; Organic Chemicals

Study Officials

• Shehryar Ahmed, MS

  Department of anesthesia Rashid Latif Medical college, Lahore, Pakistan

  PRINCIPAL INVESTIGATOR

• Syed Shakeel Ahmed, FCPS

  Department of Anesthesia, Shahida Islam Teaching Hospital, Lodhran, Pakistan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Research Consultant

Study Record Dates

• First Submitted: October 7, 2024
• First Posted: October 15, 2024
• Study Start: January 1, 2024
• Primary Completion: June 30, 2024
• Study Completion: June 30, 2024
• Last Updated: October 15, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)